Neumora Therapeutics, Inc.
NMRA
$1.28
-$0.12-8.57%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 51.39% | 4.93% | 63.50% | 47.86% | 56.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.59% | 34.79% | 51.73% | 53.38% | 63.10% |
| Operating Income | -25.59% | -34.79% | -51.73% | -53.38% | -63.10% |
| Income Before Tax | 45.77% | -36.71% | -51.97% | -50.80% | -285.35% |
| Income Tax Expenses | -100.00% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 45.90% | -36.81% | -52.30% | -50.80% | -286.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.90% | -36.81% | -52.30% | -50.80% | -286.31% |
| EBIT | -25.59% | -34.79% | -51.73% | -53.38% | -63.10% |
| EBITDA | -25.70% | -34.92% | -51.97% | -53.59% | -63.34% |
| EPS Basic | 48.64% | 59.97% | 71.14% | 72.05% | 28.46% |
| Normalized Basic EPS | -25.36% | 60.00% | 71.20% | 72.04% | 70.70% |
| EPS Diluted | 48.64% | 59.97% | 71.14% | 72.05% | 28.46% |
| Normalized Diluted EPS | -25.36% | 60.00% | 71.20% | 72.04% | 70.70% |
| Average Basic Shares Outstanding | 5.33% | 241.77% | 427.75% | 439.48% | 439.95% |
| Average Diluted Shares Outstanding | 5.33% | 241.77% | 427.75% | 439.48% | 439.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
